Skye Bioscience (SKYE) has issued an announcement.
To secure its spot on The Nasdaq Capital Market, the Company has disclosed an unaudited pro forma balance sheet showcasing its financial position following recent capital-raising efforts and a real estate sale. This move was crucial to demonstrate compliance with Nasdaq’s $5 million stockholders’ equity requirement. The balance sheet reflects the Company’s financials as if these transactions occurred at the end of the last fiscal year, bolstering confidence in its financial stability among investors and market watchers.
For a thorough assessment of SKYE stock, go to TipRanks’ Stock Analysis page.
